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Pulmonary fibrosis secondary to COVID-19: a call to arms?
As of May 6, 2020, nearly 3·7 million people have 
been infected and around 260 000 people have 
died from coronavirus disease 2019 (COVID-19) 
worldwide.1 Almost all COVID-19-related serious 
consequences feature pneumonia.2 In the first large 
series of hospitalised patients (n=138) with COVID-19 
in Wuhan, China, chest CT showed bilateral ground 
glass opacities with or without consolidation and with 
lower lobe predilection in all patients.3 In this series, 
36 (26%) patients required intensive care, of whom 
22 (61%) developed acute respiratory distress syndrome 
(ARDS).3 The mechanisms through which severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) 
causes lung damage are only partly known, but plausible 
contributors include a cytokine release syndrome 
triggered by the viral antigen, drug-induced pulmonary 
toxicity, and high airway pressure and hyperoxia-
induced acute lung injury secondary to mechanical 
ventilation. To date, about 1·2 million people worldwide 
have recovered from COVID-19, but there remains 
concern that some organs, including the lungs, might 
have long-term impairment following infection (figure). 
No post-discharge imaging or functional data are 
available for patients with COVID-19.
Other strains of the coronavirus family, namely severe 
acute respiratory syndrome coronavirus (SARS-CoV; 
known as SARS) and Middle East respiratory syndrome 
coronavirus (MERS-CoV; known as MERS), are 
genetically similar to SARS-CoV-2 and cause pulmonary 
syndromes similar to COVID-19. At the end of the 
SARS epidemic in June, 2003, 8422 individuals were 
affected and 916 died; whereas MERS, which was first 
identified in April, 2012, has infected 2519 individuals 
worldwide to date, including 866 deaths.4 The 
predominant CT abnormalities in patients with SARS 
included rapidly progressive ground glass opacities 
sometimes with consolidation. Reticular changes were 
evident approximately 2 weeks after symptom onset 
and persisted in half of patients beyond 4 weeks.5 
However, a 15-year follow-up study of 71 patients 
with SARS showed that interstitial abnormalities and 
functional decline recovered over the first 2 years 
following infection and then remained stable. At 
15 years, 4·6% (SD 6·4%) of the lungs showed interstitial 
abnormality in patients who had been infected with 
SARS.6 In patients with MERS, typical CT abnormalities 
included bilateral ground glass opacities, predominantly 
in the basal and peripheral lung zones. Follow-up 
outcomes are less well described in patients with MERS. 
In a study of 36 patients who had recovered from MERS, 
chest x-rays taken a median of 43 (range 32–320) days 
after hospital discharge showed abnormalities described 
as lung fibrosis in about a third of the patients.7 Longer-
term follow-up of patients who recovered from MERS 
has not been reported.
Pulmonary fibrosis can develop either following 
chronic inflammation or as a primary, genetically 
influenced, and age-related fibroproliferative process, 
as in idiopathic pulmonary fibrosis (IPF). Pulmonary 
fibrosis is a recognised sequelae of ARDS. However, 
most follow-up studies—which have included both 
physiological measures and chest CT—have shown that 
persistent radiographic abnormalities after ARDS are of 
little clinical relevance and have become less common 
in the era of protective lung ventilation.8 Available data 
indicate that about 40% of patients with COVID-19 
develop ARDS, and 20% of ARDS cases are severe.9 Of 
note, the average age of patients hospitalised with 
severe COVID-19 appears to be older than that seen with 
MERS or SARS, which is perhaps a consequence of wider 
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Figure: Lung CT of a patient with coronavirus disease 2019
(A) Images of peripheral mild ground glass opacities in the left lower lobe 
(arrow). (B) Three weeks later, at the same lung zones, the disease has rapidly 
progressed and fibrotic changes are now evident (arrows).
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community spread. In inflammatory lung disorders, 
such as those associated with autoimmune disease, 
advancing age is a risk factor for the development 
of pulmonary fibrosis. Given these observations, the 
burden of pulmonary fibrosis after COVID-19 recovery 
could be substantial.
Progressive, fibrotic irreversible interstitial lung 
disease, which is characterised by declining lung 
function, increasing extent of fibrosis on CT, worsening 
symptoms and quality of life, and early mortality,10 
arises, with varying degrees of frequency, in the context 
of a number of conditions including IPF, hypersensitivity 
pneumonitis, autoimmune disease, and drug-induced 
interstitial lung disease. Although the virus is eradicated 
in patients who have recovered from COVID-19, the 
removal of the cause of lung damage does not, in 
itself, preclude the development of progressive, fibrotic 
irreversible interstitial lung disease. Furthermore, even 
a relatively small degree of residual but non-progressive 
fibrosis could result in considerable morbidity and 
mortality in an older population of patients who had 
COVID-19, many of whom will have pre-existing 
pulmonary conditions.
At present, the long-term pulmonary consequences 
of COVID-19 remains speculative and should not 
be assumed without appropriate prospective study. 
Nonetheless, given the huge numbers of individuals 
affected by COVID-19, even rare complications will 
have major health effects at the population level. It is 
important that plans are made now to rapidly identify 
whether the development of pulmonary fibrosis occurs 
in the survivor population. By doing this, we can hope 
to deliver appropriate clinical care and urgently design 
interventional trials to prevent a second wave of late 
mortality associated with this devastating pandemic.
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